1. Home
  2. QNTM vs IVVD Comparison

QNTM vs IVVD Comparison

Compare QNTM & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QNTM
  • IVVD
  • Stock Information
  • Founded
  • QNTM 1998
  • IVVD 2020
  • Country
  • QNTM Canada
  • IVVD United States
  • Employees
  • QNTM N/A
  • IVVD N/A
  • Industry
  • QNTM
  • IVVD Biotechnology: Pharmaceutical Preparations
  • Sector
  • QNTM
  • IVVD Health Care
  • Exchange
  • QNTM NYSE
  • IVVD Nasdaq
  • Market Cap
  • QNTM 69.3M
  • IVVD 69.0M
  • IPO Year
  • QNTM N/A
  • IVVD 2021
  • Fundamental
  • Price
  • QNTM $25.15
  • IVVD $0.79
  • Analyst Decision
  • QNTM
  • IVVD Strong Buy
  • Analyst Count
  • QNTM 0
  • IVVD 3
  • Target Price
  • QNTM N/A
  • IVVD $5.85
  • AVG Volume (30 Days)
  • QNTM 188.7K
  • IVVD 1.2M
  • Earning Date
  • QNTM 08-13-2025
  • IVVD 08-13-2025
  • Dividend Yield
  • QNTM N/A
  • IVVD N/A
  • EPS Growth
  • QNTM N/A
  • IVVD N/A
  • EPS
  • QNTM N/A
  • IVVD N/A
  • Revenue
  • QNTM N/A
  • IVVD $36,688,000.00
  • Revenue This Year
  • QNTM N/A
  • IVVD $345.16
  • Revenue Next Year
  • QNTM N/A
  • IVVD $161.08
  • P/E Ratio
  • QNTM N/A
  • IVVD N/A
  • Revenue Growth
  • QNTM N/A
  • IVVD N/A
  • 52 Week Low
  • QNTM $2.70
  • IVVD $0.35
  • 52 Week High
  • QNTM $38.25
  • IVVD $2.74
  • Technical
  • Relative Strength Index (RSI)
  • QNTM 61.07
  • IVVD 53.94
  • Support Level
  • QNTM $21.63
  • IVVD $0.75
  • Resistance Level
  • QNTM $24.61
  • IVVD $0.86
  • Average True Range (ATR)
  • QNTM 2.37
  • IVVD 0.04
  • MACD
  • QNTM 0.27
  • IVVD 0.01
  • Stochastic Oscillator
  • QNTM 91.60
  • IVVD 63.54

About QNTM QUANTUM BIOPHARMA LTD

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: